scholarly journals Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective

2019 ◽  
Vol 92 (1) ◽  
pp. 1-14 ◽  
Author(s):  
Paulo F. Collett-Solberg ◽  
Geoffrey Ambler ◽  
Philippe F. Backeljauw ◽  
Martin Bidlingmaier ◽  
Beverly M.K. Biller ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Research Society ◽  
International Perspective ◽  
Hormone Research

scholarly journals Pituitary Stalk Interruption Syndrome: Diagnostic Delay and Sensitivity of the Auxological Criteria of the Growth Hormone Research Society

PLoS ONE ◽  
2011 ◽  
Vol 6 (1) ◽  
pp. e16367 ◽  
Author(s):  
Géraldine Gascoin-Lachambre ◽  
Raja Brauner ◽  
Laetitia Duche ◽  
Martin Chalumeau
Keyword(s):  
Growth Hormone ◽  
Diagnostic Delay ◽  
Research Society ◽  
Pituitary Stalk ◽  
Hormone Research

scholarly journals Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations

2016 ◽  
Vol 174 (6) ◽  
pp. C1-C8 ◽  
Author(s):  
Jens Sandahl Christiansen ◽  
Philippe F Backeljauw ◽  
Martin Bidlingmaier ◽  
Beverly M K Biller ◽  
Margaret C S Boguszewski ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Cost Benefit ◽  
Research Society ◽  
Breakout Session ◽  
Text Revision ◽  
Hormone Research ◽  
Potential Safety ◽  
Society Perspective ◽  
Long Acting ◽  
The Impact

Objective The Growth Hormone (GH) Research Society (GRS) convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting growth hormone preparations (LAGH). Participants A closed meeting of 55 international scientists with expertise in GH, including pediatric and adult endocrinologists, basic scientists, regulatory scientists, and participants from the pharmaceutical industry. Evidence Current literature was reviewed for gaps in knowledge. Expert opinion was used to suggest studies required to address potential safety and efficacy issues. Consensus process Following plenary presentations summarizing the literature, breakout groups discussed questions framed by the planning committee. Attendees reconvened after each breakout session to share group reports. A writing team compiled the breakout session reports into a draft document that was discussed and revised in an open forum on the concluding day. This was edited further and then circulated to attendees from academic institutions for review after the meeting. Participants from pharmaceutical companies did not participate in the planning, writing, or in the discussions and text revision on the final day of the workshop. Scientists from industry and regulatory agencies reviewed the manuscript to identify any factual errors. Conclusions LAGH compounds may represent an advance over daily GH injections because of increased convenience and differing phamacodynamic properties, providing the potential for improved adherence and outcomes. Better methods to assess adherence must be developed and validated. Long-term surveillance registries that include assessment of efficacy, cost-benefit, disease burden, quality of life, and safety are essential for understanding the impact of sustained exposure to LAGH preparations.

scholarly journals Growth Hormone Research Society perspective on biomarkers of GH action in children and adults

2018 ◽  
Vol 7 (3) ◽  
pp. R126-R134 ◽  
Author(s):  
Gudmundur Johannsson ◽  
Martin Bidlingmaier ◽  
Beverly M K Biller ◽  
Margaret Boguszewski ◽  
Felipe F Casanueva ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Symptom Relief ◽  
Research Society ◽  
Height Velocity ◽  
Breakout Session ◽  
Clinical Endpoint ◽  
Gh Treatment ◽  
Clinical Endpoints ◽  
Hormone Research ◽  
Igf I

Objective The Growth Hormone Research Society (GRS) convened a Workshop in 2017 to evaluate clinical endpoints, surrogate endpoints and biomarkers during GH treatment of children and adults and in patients with acromegaly. Participants GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry. Evidence Current literature was reviewed and expert opinion was utilized to establish the state of the art and identify current gaps and unmet needs. Consensus process Following plenary presentations, breakout groups discussed questions framed by the planning committee. The attendees re-convened after each breakout session to share the group reports. A writing team compiled the breakout session reports into a document that was subsequently discussed and revised by participants. This was edited further and circulated for final review after the meeting. Participants from pharmaceutical companies were not part of the writing process. Conclusions The clinical endpoint in paediatric GH treatment is adult height with height velocity as a surrogate endpoint. Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH-deficient patients (GHDA) and in patients with acromegaly. The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of comorbidities are used in acromegaly. Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment, whereas in acromegaly, normalization of IGF-I may be related to improvement in mortality. There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

Sign in / Sign up

Export Citation Format

Share Document